MELBOURNE, Australia, July 12, 2010 - Australian regenerative medicine company, Mesoblast Limited (ASX: MSB; ADR: MBLTY), today announced that based on positive results from its bone marrow transplant clinical trial conducted at the University of Texas MD Anderson Cancer Center, a formal meeting has been scheduled with the United States Food and Drug Administration (FDA) to discuss a proposed Phase 3 clinical trial program.

LONDON, July 12, 2010 - MRC Technology (UK) announced today that it has entered into an agreement with Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) for an exclusive licence to a series of small molecule drug candidates for the potential treatment of neurological disease.